GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Personal Services » Medifast Inc (NYSE:MED) » Definitions » EBIT

Medifast (Medifast) EBIT : $126 Mil (TTM As of Dec. 2023)


View and export this data going back to 1981. Start your Free Trial

What is Medifast EBIT?

Medifast's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $126 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medifast's annualized ROC % for the quarter that ended in Dec. 2023 was 22.08%. Medifast's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 50.93%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Medifast's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 52.83%.


Medifast EBIT Historical Data

The historical data trend for Medifast's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medifast EBIT Chart

Medifast Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 91.04 134.16 216.24 184.76 126.40

Medifast Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.55 53.51 38.71 25.51 8.68

Competitive Comparison of Medifast's EBIT

For the Personal Services subindustry, Medifast's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medifast's EV-to-EBIT Distribution in the Personal Services Industry

For the Personal Services industry and Consumer Cyclical sector, Medifast's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medifast's EV-to-EBIT falls into.



Medifast EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $126 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medifast  (NYSE:MED) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medifast's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=34.704 * ( 1 - 38.43% )/( (101.215 + 92.338)/ 2 )
=21.3672528/96.7765
=22.08 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=320.019 - 104.64 - ( 157.76 - max(0, 110.112 - 224.276+157.76))
=101.215

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Medifast's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=34.704/( ( (69.165 + max(-38.124, 0)) + (67.112 + max(-12.427, 0)) )/ 2 )
=34.704/( ( 69.165 + 67.112 )/ 2 )
=34.704/68.1385
=50.93 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 58.227 + 8.289) - (104.64 + 0 + 0)
=-38.124

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 54.591 + 19.397) - (85.841 + 0.574 + 0)
=-12.427

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Medifast's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=126.401/239.262
=52.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medifast EBIT Related Terms

Thank you for viewing the detailed overview of Medifast's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Medifast (Medifast) Business Description

Traded in Other Exchanges
Address
100 International Drive, Baltimore, MD, USA, 21202
Medifast Inc is a United states based company that produces, distributes and sells products concerning weight loss, weight management, and healthy living. The company generates its revenue from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other consumable health and nutritional products.
Executives
Jeffrey J Brown director 19900 MACARTHUR BLVD, SUITE 570, IRVINE CA 92612
Andrea B Thomas director C/O MEDIFAST, INC., 100 INTERNATIONAL DRIVE, BALTIMORE MD 21202
Michael A. Hoer director MEDIFAST, INC., 100 INTERNATIONAL DRIVE, 18TH FLOOR, BALTIMORE MD 21202
Scott Schlackman director 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Hallquist Constance J. director 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Elizabeth A. Geary director C/O MEDIFAST, INC., 100 INTERNATIONAL DRIVE, BALTIMORE MD 21202
Daniel R Chard director, officer: Chief Executive Officer NU SKIN ENTERPRISES, INC., 75 WEST CENTER STREET, PROVO UT 84601
Jonathan Barrett Mackenzie officer: VP, Finance & CAO 100 INTERNATIONAL DRIVE, BALTIMORE MD 21202
Kevin G Byrnes director C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Michael C Macdonald director C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117
James P. Maloney officer: Chief Financial Officer 415 HOLIDAY DRIVE, PITTSBURGH PA 15220
Ming Xian director MEDIFAST, INC., 100 INTERNATIONAL DRIVE, 18TH FLOOR, BALTIMORE MD 21202
Carl E Sassano director C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Joseph P Kelleman officer: (Interim) CFO 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Timothy G Robinson officer: Chief Financial Officer C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117